RLYB
RallybioDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
RLYB116 translates into a clear development path (partner or internal Phase 2 plan) and the company stabilizes clinical leadership—market re-rates toward analyst upside with multiplex expansion.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Clinical execution and timing risk for RLYB116
Momentum
88
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.50 · Bull $15.00 · Bear $4.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-06 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $1.00
Why
Momentum88 · Δ7d -
Value41 · Δ7d +0.1
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
88
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
0
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 88.0 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$85.99M
Beta
-1.05
Shares Out
42.24M
P/E (TTM) · Derived
-1.5
P/S (TTM)
42.56
P/FCF (TTM) · Derived
-2.61
Rev YoY
-29.1%
EPS YoY
+238.2%
Gross Margin
-
Op Margin
-5870.0%
Net Debt
-$65.51M
Current Ratio
14.74
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology